[go: up one dir, main page]

WO1999043361A8 - Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates - Google Patents

Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates

Info

Publication number
WO1999043361A8
WO1999043361A8 PCT/DK1999/000080 DK9900080W WO9943361A8 WO 1999043361 A8 WO1999043361 A8 WO 1999043361A8 DK 9900080 W DK9900080 W DK 9900080W WO 9943361 A8 WO9943361 A8 WO 9943361A8
Authority
WO
WIPO (PCT)
Prior art keywords
glp
helix
aggregates
derivatives
content exceeding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK1999/000080
Other languages
French (fr)
Other versions
WO1999043361A1 (en
Inventor
Liselotte Bjerre Knudsen
Per Olaf Huusfeldt
Per Franklin Nielsen
Niels C Kaarsholm
Helle Birk Olsen
Lars Thim
Soeren Erik Bjoern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to JP2000533156A priority Critical patent/JP2002504527A/en
Priority to EP99907325A priority patent/EP1060192A2/en
Priority to AU27128/99A priority patent/AU2712899A/en
Publication of WO1999043361A1 publication Critical patent/WO1999043361A1/en
Publication of WO1999043361A8 publication Critical patent/WO1999043361A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a pharmaceutical composition comprising a GLP-2 derivative of improved solubility and/or stability, and to a method for improving the solubility and/or stability of GLP-2 or a fragment or an analogue thereof.
PCT/DK1999/000080 1998-02-27 1999-02-25 Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates Ceased WO1999043361A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000533156A JP2002504527A (en) 1998-02-27 1999-02-25 GLP-2 derivatives with more than 25% helical component forming partially organized micellar-like aggregates
EP99907325A EP1060192A2 (en) 1998-02-27 1999-02-25 Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
AU27128/99A AU2712899A (en) 1998-02-27 1999-02-25 Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK27198 1998-02-27
DK0271/98 1998-02-27

Publications (2)

Publication Number Publication Date
WO1999043361A1 WO1999043361A1 (en) 1999-09-02
WO1999043361A8 true WO1999043361A8 (en) 1999-10-14

Family

ID=8091669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1999/000080 Ceased WO1999043361A1 (en) 1998-02-27 1999-02-25 Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates

Country Status (4)

Country Link
EP (1) EP1060192A2 (en)
JP (1) JP2002504527A (en)
AU (1) AU2712899A (en)
WO (1) WO1999043361A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
DE60134251D1 (en) 2000-09-18 2008-07-10 Sanos Bioscience As USE OF GLP-2 PEPTIDES
ES2307718T3 (en) 2001-02-16 2008-12-01 Conjuchem Biotechnologies Inc. PEPTIDE 2 SIMILAR TO FLUCAGON (GLP-2) OF PROLONGED DURATION FOR THE TREATMENT OF GASTROINTESTINAL DISEASES AND DISORDERS.
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
CN1771080B (en) 2003-04-08 2010-12-15 诺沃挪第克公司 Method for producing a therapeutic polypeptide or a precursor thereof comprising at least one chromatographic step
WO2004089985A1 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
EP2292254A3 (en) 2003-06-03 2011-12-14 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
CN1812808B (en) 2003-06-03 2012-07-04 诺沃挪第克公司 Stabilized pharmaceutical peptide compositions
CA2539253A1 (en) * 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
RU2401276C2 (en) * 2003-09-19 2010-10-10 Ново Нордиск А/С Glucagon-like peptide-1 (glp-1) derivatives
TW200522976A (en) * 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
CN100444898C (en) * 2003-09-19 2008-12-24 诺沃挪第克公司 Albumin-binding derivatives of therapeutic peptides
WO2006050244A2 (en) 2004-11-01 2006-05-11 Nps Allelix Corp. Treatment of short bowel syndrome patients with colon-in-continuity
WO2006097535A2 (en) * 2005-03-18 2006-09-21 Novo Nordisk A/S Peptide agonists of the glucagon family with secretin like activity
BRPI0608516A2 (en) 2005-03-18 2010-11-16 Novo Nordisk As glp-1 analog, method for increasing the time of action in a patient of a glp-1 analog, pharmaceutical composition, and use of a compound
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
CN100418983C (en) * 2005-05-11 2008-09-17 中国药科大学 Human glucagon related peptide-2 analog
JP2011520844A (en) 2008-05-15 2011-07-21 ノボ・ノルデイスク・エー／エス Purification of peptides prepared by solid phase synthesis
WO2010015668A1 (en) 2008-08-06 2010-02-11 Novo Nordisk A/S Conjugated proteins with prolonged in vivo efficacy
AU2010207725B2 (en) 2009-01-22 2015-06-11 Novo Nordisk Health Care Ag Stable growth hormone compounds
JP6086528B2 (en) 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Growth hormone with long-term in vivo efficacy
WO2011089250A2 (en) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Stable growth hormone compounds
CA2787890C (en) 2010-01-22 2020-01-14 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
EP2981282B1 (en) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Growth hormone compound formulation
WO2019086559A1 (en) 2017-10-31 2019-05-09 Adocia Composition comprising a glp-2 receptor agonist and a co-polyamino acid carrying carboxylate charges and hydrophobic radicals
US20200254065A1 (en) 2019-02-11 2020-08-13 Opko Biologics Ltd. Long-acting glp-2 analogs
EP4281039A2 (en) 2021-01-25 2023-11-29 Mylan Ireland Limited Pharmaceutical glp peptide compositions and methods of preparation thereof
TW202327643A (en) * 2021-09-10 2023-07-16 丹麥商西蘭製藥公司 Process for formulating compositions comprising glucagon-like-peptide-2(glp-2) analogues

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132404A3 (en) * 1993-09-17 2002-03-27 Novo Nordisk A/S Acylated insulin
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
EP0891378B1 (en) * 1996-03-01 2002-11-13 Novo Nordisk A/S Use of a pharmaceutical composition comprising an appetite-suppressing peptide
DK1231219T3 (en) * 1996-04-12 2010-12-20 Ontario Inc 1149336 GLucagon-like peptide-2 analogs
AU4112497A (en) * 1996-08-30 1998-03-19 Novo Nordisk A/S Glp-2 derivatives

Also Published As

Publication number Publication date
JP2002504527A (en) 2002-02-12
WO1999043361A1 (en) 1999-09-02
EP1060192A2 (en) 2000-12-20
AU2712899A (en) 1999-09-15

Similar Documents

Publication Publication Date Title
WO1999043361A8 (en) Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
AU2610799A (en) Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates
HUP0003305A3 (en) Hiv protease inhibiting tetrahydro-pyrimid-2-on derivative, pharmaceutical compositions containing it and process for producing the compound
CA2370565A1 (en) Dermally applicable vitamin d-containing pharmaceutical compositions
WO2000046069A3 (en) Ignition enhanced gas generant and method
AU2001269198A1 (en) Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them
AU2839801A (en) Aromas and aroma compositions containing 4,8-dimethyl-3,7-nonadien-2-one, and a method for the production thereof
AU3031797A (en) New substituted 2,4-thiazolidinedione derivatives, processes for producing them and pharmaceutical compositions containing them
HUP0204157A3 (en) 1,3-dihydro-2h-indol-2-one derivatives, process for preparation of the compounds and pharmaceutical compositions containing the same
MY127953A (en) Gabapentin-containing solid compositions and process for preparing the same
AU2001235737A1 (en) Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same
CA2343732A1 (en) Substituted .gamma.-phenyl-.delta.-lactones and analogs thereof and uses related thereto
AU2002218075A1 (en) Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them
ID27765A (en) GEL PLESTER THAT CONTAINS STEROID AND THE PROCESS OF MAKING IT
AU4134297A (en) 2,4-disubstituted pyrimidine derivatives, process for producing the same, and medicinal compositions containing the same
HUP9701660A3 (en) 10,13,15-trioxatricyclo[9.2.1.1.9.6]pentadekanon derivatives, process for producing them, and pharmaceutical compositions containing them
IL129616A0 (en) Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
CA2296560A1 (en) Amino acid derivatives useful to treat stroke
HUT74615A (en) 2,3-cyclic-condensed-1,4-dihydro-pyridine derivatives, process for producing them and pharmaceutical compositions containing the same
HUP0204430A3 (en) Method for the enzymatic resolution of the racemates of aminomethyl-aryl-cyclohexanol derivatives, the obtained new compounds and pharmaceutical compositions containing thereof
AU3825700A (en) Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines
PL350243A1 (en) (1-phenacy-3-phenyl-3-piperidylethyl)piperidine derivatives, method for the production thereof and pharmaceutical compositions containing the same
IL129627A0 (en) Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
HU9900263D0 (en) 11-acetyl-12,13-dioxabicyclo[8.2.1.]tridecenon derivatives, process for producing them and pharmaceutical compositions containing them
IL129625A0 (en) Novel (-)-enantionmers of CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999907325

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1999907325

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase in:

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999907325

Country of ref document: EP